Kerri-Ann Millar
Director of Finance/CFO at CUE BIOPHARMA, INC.
Net worth: 23 327 $ as of 30/05/2024
Profile
Kerri-Ann Millar is currently the Chief Financial Officer at Cue Biopharma, Inc. since 2020.
Prior to this, she worked as a Controller at Flexion Therapeutics, Inc. from 2014 to 2017.
She completed her undergraduate degree at Boston University in 1992.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
CUE BIOPHARMA, INC.
0.03% | 04/06/2024 | 14,311 ( 0.03% ) | 23 327 $ | 30/05/2024 |
Kerri-Ann Millar active positions
| Companies | Position | Start |
|---|---|---|
| CUE BIOPHARMA, INC. | Director of Finance/CFO | 29/04/2018 |
Former positions of Kerri-Ann Millar
| Companies | Position | End |
|---|---|---|
| FLEXION THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 31/08/2017 |
Training of Kerri-Ann Millar
| Boston University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| CUE BIOPHARMA, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Flexion Therapeutics, Inc.
 Flexion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA. | Health Technology |
- Stock Market
- Insiders
- Kerri-Ann Millar
